Department of Thoracic Surgery, Peking University People's Hospital, Beijing 100044, China.
Center of Mini-invasive Thoracic Surgery, Peking University People's Hospital, Beijing 100044, China.
Chin Med J (Engl). 2022 Jun 5;135(11):1264-1271. doi: 10.1097/CM9.0000000000002198.
Primary palmar hyperhidrosis (PPH) is a pathologic condition of excessive sweating on hands that has adverse impacts on patients' social activity, professional life, and psychological state. Endoscopic thoracic sympathicotomy (ETS) is by far the treatment choice for PPH with the most stable and durable curative effects, but special attention should be given to the side effects of the surgery, especially compensatory hyperhidrosis (CH). This consensus is the second version of the Chinese Expert Consensus on the Surgical Treatment of PPH by the China Expert Committee on Palmar Hyperhidrosis (CECPH), which was published 10 years ago. This consensus emphasizes the need for special attention and careful assessment of the patients' feelings, as well as their emotional and mental state, and emphasizes that distress due to palmar sweating and the desire for treatment are prerequisites for diagnosis. It also provides a more nuanced delineation of CH and reviews all new attempts to prevent and treat this side effect. New evidence of the epidemiology, pathogenesis of PPH, and indications for surgery were also assessed or recommended.
原发性手掌多汗症（PPH）是一种手部过度出汗的病理状况，会对患者的社交活动、职业生涯和心理状态产生不良影响。胸腔镜胸交感神经切除术（ETS）是迄今为止治疗 PPH 的首选方法，其疗效最稳定持久，但应特别注意手术的副作用，尤其是代偿性多汗症（CH）。本共识是中国手掌多汗症专家委员会（CECPH）10 年前发布的《原发性手掌多汗症手术治疗中国专家共识》的第二版。本共识强调需要特别关注和仔细评估患者的感受以及他们的情绪和精神状态，并强调手掌出汗引起的不适和治疗的愿望是诊断的前提。它还对 CH 进行了更细致的描述，并回顾了所有预防和治疗这种副作用的新尝试。还评估或推荐了新的 PPH 流行病学、发病机制和手术适应证的证据。
